Capecitabine Dosing and Management
Standard Dosing Recommendations
For colorectal cancer, start capecitabine at 1250 mg/m² orally twice daily for 14 days followed by a 7-day rest period (21-day cycles), and for breast cancer use the same dose or 825-1000 mg/m² twice daily when combined with docetaxel. 1, 2
Colorectal Cancer Dosing
Adjuvant Treatment (Stage III):
- Monotherapy: 1250 mg/m² twice daily, days 1-14, every 3 weeks for 8 cycles (24 weeks total) 1, 2
- CapeOx (with oxaliplatin): 1000 mg/m² twice daily, days 1-14, every 3 weeks 1, 3
Metastatic Disease:
- Monotherapy: 1250 mg/m² twice daily, days 1-14, every 3 weeks 1, 4
- CapeOx: 1000 mg/m² twice daily, days 1-14, every 3 weeks with oxaliplatin 130 mg/m² day 1 1, 4
Breast Cancer Dosing
Monotherapy: 1250 mg/m² twice daily, days 1-14, every 3 weeks 2
Combination with Docetaxel: 825 mg/m² twice daily, days 1-14, every 3 weeks 5
Adjuvant for Triple-Negative with Residual Disease: Up to 6-8 cycles of capecitabine 825 mg/m² twice daily after neoadjuvant therapy 5
Important Note on North American Dosing: Evidence suggests North American patients experience greater toxicity with capecitabine than European patients 1. Many US oncologists routinely reduce starting doses to 1000 mg/m² twice daily for monotherapy, though this lower dose has not been validated in large randomized trials 6, 7.
Renal Impairment Dose Adjustments
Renal function is the most critical factor requiring dose modification with capecitabine. 2, 8, 9
Dosing Algorithm by Creatinine Clearance:
- CrCl >50 mL/min: Full standard dose (1250 mg/m² twice daily for monotherapy)
- CrCl 30-50 mL/min (moderate impairment): Reduce starting dose to 75% of standard dose (approximately 950 mg/m² twice daily) 2, 8, 9
- CrCl <30 mL/min (severe impairment): Contraindicated - do not use capecitabine 2, 8
Critical Considerations:
Use the Cockcroft-Gault equation to calculate creatinine clearance - this is what the FDA label and clinical trials used 2. Be aware that standardized creatinine measurements may underestimate renal impairment; patients with borderline function (CrCl 50-60 mL/min) may actually have "pseudo-normal" function and require closer monitoring 10.
Pharmacokinetic rationale: Moderate renal impairment increases systemic exposure to 5'-DFUR by 42% and FBAL by 85-109%, which correlates directly with increased toxicity 8. Severe renal impairment causes a 258% increase in FBAL exposure 2.
Safety data: All patients with severe renal impairment in pharmacokinetic studies experienced grade 3-4 adverse events 8. Patients with moderate impairment have significantly higher rates of grade 3-4 toxicities compared to those with normal function 9.
Toxicity-Based Dose Modifications
Implement a structured dose reduction and interruption strategy based on specific toxicities. 2
Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia):
- Grade 1: Continue at same dose
- Grade 2 (first occurrence): Interrupt until resolved to grade 0-1, then resume at same dose
- Grade 2 (second occurrence): Interrupt until resolved, then resume at 75% of dose
- Grade 3: Interrupt until resolved to grade 0-1, then resume at 50% of dose
- Grade 4: Discontinue permanently
Diarrhea:
- Grade 2: Interrupt until resolved to grade 0-1, then resume at same dose
- Grade 3: Interrupt until resolved, then resume at 75% of dose
- Grade 4: Discontinue permanently
Stomatitis:
- Grade 2: Interrupt until resolved to grade 0-1, then resume at same dose
- Grade 3-4: Interrupt until resolved, then resume at 75% of dose
Hematologic Toxicity:
- Grade 3-4 neutropenia or thrombocytopenia: Interrupt until resolved to grade ≤1, then resume at 75% of dose
Dose Reduction Schedule:
- First reduction: 75% of starting dose (approximately 950 mg/m² twice daily if started at 1250 mg/m²)
- Second reduction: 50% of starting dose (approximately 625 mg/m² twice daily)
- If toxicity persists at 50% dose: Discontinue permanently
Hepatic Impairment
Mild to moderate hepatic dysfunction requires caution but no specific dose reduction is mandated by FDA labeling. 2
Pharmacokinetic data show capecitabine AUC and Cmax increase by 60% in patients with hepatic dysfunction due to liver metastases, but 5-FU exposure remains unchanged 2. Monitor closely for toxicity and consider empiric dose reduction to 75% of standard dose in patients with significant hepatic impairment 11.
Severe hepatic dysfunction: No data available; use with extreme caution or avoid 2.
Special Populations and Considerations
Elderly Patients:
Age alone does not require dose reduction, but elderly patients (≥65 years) have higher risk of toxicity. 12
In the CALGB 49907 trial, patients ≥65 years starting at 1250 mg/m² twice daily had a 34% rate of grade ≥3 toxicity, including two treatment-related deaths 5. The protocol was amended to start at 1000 mg/m² twice daily for all subsequent elderly patients 5.
Recommendation: For patients ≥65 years, particularly those ≥75 years or with multiple comorbidities, start at 1000 mg/m² twice daily and monitor closely in the first two cycles 5, 12.
DPYD Deficiency:
Consider DPYD genotyping before starting capecitabine, particularly in patients with prior severe fluoropyrimidine toxicity. 13
- Heterozygous DPYD variants (intermediate metabolizers): Reduce starting dose by 25-50% depending on specific variant
- Homozygous DPYD variants (poor metabolizers): Avoid fluoropyrimidines entirely 13
Food Effects:
Always administer capecitabine within 30 minutes after a meal - food reduces Cmax by 60% and AUC by 35%, which actually improves tolerability without compromising efficacy 2.
Common Pitfalls to Avoid
Do not use standardized creatinine values directly in Cockcroft-Gault without adjustment - this may lead to overdosing in patients with borderline renal function 10
Do not arbitrarily reduce doses below validated levels in CapeOx regimens - the 1000 mg/m² twice daily dose is the only validated dose for CapeOx from the IDEA trial 3
Do not continue capecitabine at full dose after first occurrence of grade 2-3 toxicity - early dose modification prevents severe toxicity without compromising efficacy 2, 9
Do not use capecitabine in patients with CrCl <30 mL/min - this is an absolute contraindication 2, 8
Do not forget to monitor for drug interactions - capecitabine increases warfarin effect (57% increase in S-warfarin AUC) and phenytoin levels 2
Do not assume all patients tolerate 1250 mg/m² twice daily - approximately 40-50% of patients require dose modifications, and North American patients may need lower starting doses 2, 6, 7